• GSK is trading 4% up at £2040.00 today, following the US FDA's approval of its lung cancer drug, Jideytro.
  • The approval marks a major milestone in GSK's oncology portfolio, driving significant buying interest.
  • Broader strength across the healthcare sector and ongoing institutional rotation are providing additional tailwinds for the stock.